P/E ratio for Viking Therapeutics (VKTX)
P/E ratio as of May 2024 (TTM): -81.5
According to Viking Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -81.4624. At the end of 2022 the company had a P/E ratio of -10.3.
P/E ratio history for Viking Therapeutics from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -10.3 | 61.68% |
| 2021 | -6.39 | -38.72% |
| 2020 | -10.4 | -51.9% |
| 2019 | -21.7 | 10.5% |
| 2018 | -19.6 | 286.51% |
| 2017 | -5.08 | 326.47% |
| 2016 | -1.19 | -2.85% |
| 2015 | -1.22 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Ultragenyx RARE | -4.22 | -94.82% | 🇺🇸 USA |
 Repligen
RGEN | 79.6 | -197.68% | 🇺🇸 USA |
 Recro Pharma
REPH | -2.79 | -96.58% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.